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Inflammation is a series of processes designed for eventual clearance of pathogens 
and repair of damaged tissue. In the context of autoimmune recognition, inflammatory 
processes are usually considered to be pathological. This is also true for inflammatory 
responses in the central nervous system (CNS). However, as in other tissues, neuroin-
flammation can have beneficial as well as pathological outcomes. The complex role of 
encephalitogenic T cells in multiple sclerosis and its animal model experimental autoim-
mune encephalomyelitis (EAE) may derive from heterogeneity of the myeloid cells with 
which these T cells interact within the CNS. Myeloid cells, including resident microglia 
and infiltrating bone marrow-derived cells, such as dendritic cells (DC) and monocytes/
macrophages [bone marrow-derived macrophages (BMDM)], are highly heterogeneous 
populations that may be involved in neurotoxicity and also immunoregulation and 
regenerative processes. Better understanding and characterization of myeloid cell het-
erogeneity is essential for future development of treatments controlling inflammation and 
inducing neuroprotection and neuroregeneration in diseased CNS. Here, we describe 
and compare three populations of myeloid cells: CD11c+ microglia, CD11c− microglia, 
and CD11c+ blood-derived cells in terms of their pathological versus protective functions 
in the CNS of mice with EAE. Our data show that CNS-resident microglia include func-
tionally distinct subsets that can be distinguished by their expression of CD11c. These 
subsets differ in their expression of Arg-1, YM1, iNOS, IL-10, and IGF-1. Moreover, 
in contrast to BMDM/DC, both subsets of microglia express protective interferon-beta 
(IFNβ), high levels of colony-stimulating factor-1 receptor, and do not express the Th1-
associated transcription factor T-bet. Taken together, our data suggest that CD11c+ 
microglia, CD11c− microglia, and infiltrating BMDM/DC represent separate and distinct 
populations and illustrate the heterogeneity of the CNS inflammatory environment.
Keywords: microglia, eae, cD11c, myeloid cells, cns, M1/M2
September 2015 | Volume 6 | Article 4632
Wlodarczyk et al. Myeloid cell heterogeneity in EAE
Frontiers in Immunology | www.frontiersin.org
introduction
The contribution of myeloid cells to central nervous system 
(CNS) function is increasingly appreciated. This is especially 
relevant in CNS inflammation, where they can act not only as 
participants in the immune attack but also as regulators of the 
immune response and promoters of neuronal and synaptic pro-
tection and regeneration (1). A key aspect of the inflammatory 
response within the CNS is the recruitment and reactivation of 
infiltrating CD4+ T cells and direction of their effector function 
within the tissue (2). Their role in multiple sclerosis (MS) and 
its animal model experimental autoimmune encephalomyelitis 
(EAE) is complex. Although there is a consensus that inhibition 
or blockade of such responses has therapeutic benefit in MS 
and EAE [reviewed in Ref. (3)], there are numerous reports 
of beneficial effect of the activation of such T cells for myelin 
clearance, remyelination, and repair (4, 5). The cells implicated 
in interaction with CD4+ T cells within the inflamed CNS are 
myeloid cells, such as infiltrating dendritic cells (DC) and 
monocytes/macrophages, and also resident microglia (6–9). 
These are very heterogeneous populations of immune cells that 
can dampen inflammation or contribute to pathological events. 
Better characterization of the heterogeneity of blood-derived as 
well as CNS-resident myeloid cells and their interaction with 
T cells is crucial for understanding how to effectively control 
inflammation and induce neuroprotection and neuroregenera-
tion in diseases like MS.
Microglia are cells of myeloid lineage considered to be CNS 
macrophages [reviewed in Ref. (10)]. However, they differ in 
terms of origin: while macrophages originate from fetal liver, 
microglia emerge from yolk sac and colonize the CNS early 
during neonatal development (11). Microglia are autonomously 
maintained through proliferation and in normal circumstances, 
they are not replaced by bone marrow (BM)-derived cells (12). 
Based on many phenotypic similarities between microglia and 
macrophages, the discrimination between these two populations 
as well as other BM- or blood-derived cells during neuroinflam-
mation is challenging. The difference in the expression level of 
cell membrane tyrosine phosphatase CD45 can be used to dis-
criminate CD45low microglia from CD45high blood-derived cells 
by flow cytometry (13, 14). In addition, other common markers 
used for microglial identification include CD11b, CD11c, Iba1, 
and CX3CR1 (10, 15–20). However, these can also be expressed 
by macrophages as well as monocytes and DC. Recent develop-
ment of a double knock-in red (CCR2)/green (CX3CR1) mouse 
has allowed the discrimination of CNS-resident microglia from 
infiltrating leukocytes, microglia being CX3CR1-positive but, in 
contrast to infiltrating immune cells, CCR2-negative (21).
In this study, we aimed to examine the heterogeneity 
amongst microglia as well as to compare them to infiltrating 
blood-derived myeloid cells in EAE. We show that CD11c+ 
microglia, CD11c− microglia, and CD11c+ blood-derived cells 
are functionally distinct populations of myeloid cells within the 
inflamed CNS. Our findings illustrate the heterogeneity of the 
CNS inflammatory environment, reflecting the complexity of 
immunological processes that lead to pathology, tissue protec-
tion, or immunoregulation.
Materials and Methods
Mice
Female C57BL/6j bom (B6) mice aged 6–8 weeks were obtained 
from Taconic Europe A/S (Lille Skensved, Denmark) and 
CX3CR1gfp/gfp were obtained from The Jackson Laboratory (Bar 
Harbor, ME, USA) and maintained in the Biomedical Laboratory, 
University of Southern Denmark (Odense). All experiments 
were approved by the Danish Animal Experiments Inspectorate 
(approval number 2014-15-0201-00369).
induction of neuroinflammation
NMO-like disease
To induce NMO-like lesions, 7–10-week-old female B6 mice 
received IgG antibodies isolated from NMO patients and human 
complement by injection in the striatum, as described in Ref. (22). 
The use of human material was approved by The Committee on 
Biomedical Research Ethics for the Region of Southern Denmark 
(ref. no. S-20080142).
Cuprizone-induced demyelination
In order to induce demyelination, 7–12-week-old female B6 mice 
were fed with cuprizone for 4 weeks as described in Ref. (23).
EAE-model
Seven to ten weeks old female mice were immunized by injecting 
subcutaneously 100 μl of an emulsion containing 100 μg of myelin 
oligodendrocyte glycoprotein (MOG)p35–55 (TAG Copenhagen 
A/S, Frederiksberg, Denmark) in incomplete freunds adjuvant 
(DIFCO, Alberstslund, Denmark) supplemented with 400  μg 
H37Ra Mycobacterium tuberculosis (DIFCO). Bordetella pertussis 
toxin (300 ng; Sigma-Aldrich, Brøndby, Denmark) in 200 μl of 
PBS was injected intraperitoneally at day 0 and day 2. Animals 
were monitored daily from day 5 and scored on a 6-point scale as 
follows: 0, no symptoms; 0.5, partial loss of tail tonus; 1, complete 
loss of tail tonus; 2, difficulty to right, 3, paresis in one or both hind 
legs; 4, paralysis in one or both hind legs; 5, front limb paresis; 
and 6, moribund. Severe EAE usually developed 14–18 days after 
immunization and was defined as a score of 3–5.
isolation of Mononuclear cells from  
spleen and cns
Mice were anesthetized with 0.2  mg pentobarbital (200  mg/ml; 
Glostrup Apotek, Glostrup, Denmark) per gram body weight and 
intracardially perfused with ice-cold PBS. CNS tissue (Brain and 
SC from EAE model, Ipsi lateral part of the brain from NMO-like 
disease, and whole brain from Cuprizone-induced demyelination) 
was collected and a single cell suspension was generated by forcing 
through a 70 μm cell strainer (BD Biosciences). Mononuclear cells 
were collected after centrifugation on 37% Percoll (GE Healthcare 
Bio-sciences AB, Brøndby, Denmark). Spleens were digested with 
collagenase D (0.5  mg/ml; Roche, Hvidovre-Copenhagen) and 
DNase I (40 μg/ml, Roche) for 30 min at 37°C. Supernatant was col-
lected and supplemented with 100 mM EDTA for 5 min at 37°C and 
passed through a 70 μm cell strainer (BD Biosciences, Albertslund, 
Denmark). Red blood cells were lysed with a 0.83% NH4Cl solution. 
Splenocytes and CNS mononuclear cells were then incubated with 
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anti-Fc receptor (Clone 2.4G2; 1 μg/ml; BD Pharmingen) and Syrian 
hamster IgG (50 μg/ml; Jackson Immuno Research Laboratories 
Inc., Skanderborg, Denmark) in PBS 2% fetal bovine serum (FBS). 
CNS mononuclear cells were stained with PE-anti-mouse CD45 
(Biolegend, Copenhagen, Denmark), PerCP-Cy5.5-anti-mouse 
CD11b (Biolegend) and biotinylated-anti-mouse CD11c (BD 
Pharmingen) antibodies in PBS 2% FBS. Splenocytes were stained 
with PE-anti-mouse CD11c antibodies in PBS 2% FBS and CD11c+ 
cells were sorted on a FACSAria™ III cell sorter (BD Biosciences, 
Albertslund, Denmark). After excluding doublets (FSC-H, FSC-W 
and SSC-H, SSC-W) (Figures 1A–C), CNS cell populations were 
gated based on isotype control antibodies as CD45dimCD11b+CD11c− 
(CD11c− microglia), CD45dimCD11b+CD11c+ (CD11c+ microglia), 
and CD45highCD11c+ (BMDM/DC) (Figures  1D,E) and were 
sorted on a FACSAria™ III cell sorter (BD Biosciences).
Bromodeoxyuridine (BrdU) Proliferation assay
B6 mice received 100 μl of 1 mg/ml BrdU by daily intraperitoneal 
injection, starting from day 10 after immunization. Mice with 
severe EAE were sacrificed and analyzed by flow cytometry using 
BrdU flow kit (BD Pharmingen) according to the manufacturer’s 
protocol. Data were acquired on an LSRII™ flow cytometer and 
analyzed using FACSDiva™ 7 software (BD Biosciences).
FigUre 1 | gating strategy for flow cytometry and Facs-sorting. Representative flow cytometry profiles from individual central nervous system suspensions 
prepared from mice with severe EAE, showing gating strategy used for flow cytometry and FACS-sorting. First doublets were excluded from live gate (a) based on 
FSC-H, FSC-W (B) and SSC-H, SSC-W (c), then microglia were gated based on CD45 and CD11b expression (D). CD11c− microglia, CD11c+ microglia, and 
BMDM/DC population were discriminated based on CD45 and CD11c expression and gated based on isotype control antibodies (vertical line) and sorted (e).
rna extraction, reverse Transcription, and 
Quantitative real-Time Pcr
Sorted splenic CD11c+ cells from individual mice as well as 
CD11c+ microglia, CD11c− microglia, and CD45highCD11c+ 
cells from pools of 2–3 mice were placed in RLT buffer (Qiagen, 
Copenhagen, Denmark). Total RNA was extracted using RNeasy 
columns as per the manufacturer’s protocol (Qiagen). Reverse 
transcription was performed with M-MLV reverse transcriptase 
(Invitrogen) according to the manufacturer’s protocol.
Quantitative real-time PCR (qPCR) was performed with 1 μl 
cDNA in a 25 μl reaction volume containing Maxima® Probe/
ROX qPCR Master mix (Fermentas, St. Leon-rot, Germany), for-
ward and reverse primers (800 nM; from TAG Copenhagen A/S, 
Frederiksberg, Denmark) and probe (200 nM; Applied Biosystems, 
Nærum, Denmark and TAG Copenhagen A/S, Frederiksberg, 
Denmark). Primer and probe sequences were as follows: IFNβ: 
For: GCGTTCCTGCTGTGCTTCTC; Rev: TTGAAGTCCGC 
CCTGTAGGT; Probe: CGGAAATGTCAGGAGCT; IRF7: 
For: CACCCCCATCTTCGACTTCA; Rev: CCAAAACCCAG 
GTAGATGGTGTA; Probe: CACTTTCTTCCGAGAACT; IFR3: 
For: CACCCCAAGAAAATCCACTGA; Rev: AGGCGGTC 
ACCTCGAACTC; Probe: TAGCTGAGGAACAATG. TaqMan® 
PreAmp Master Mix Kits were used for T-bet: Mm01299452; 
September 2015 | Volume 6 | Article 4634
Wlodarczyk et al. Myeloid cell heterogeneity in EAE
Frontiers in Immunology | www.frontiersin.org
YM1: Mm00657889; ARG1: Mm00475988; iNOS: Mm00440502; 
CSF1R: Mm01266652. For IGF1, SYBR Green/ROX qPCR Master 
Mix (2X) Probe/ROX qPCR Master mix (Fermentas, St. Leon-rot, 
Germany) was used with forward and reverse primers (800 nM) 
from TAG Copenhagen A/S). Primer sequences were as follows: 
IGF1: For: CCG AGG GGC TTT TAC TTC AAC AA; Rev: CGG 
AAG CAA CAC TCA TCC ACA A. PCR reactions were done 
on an ABI Prism 7300 Sequence Detection System (Applied 
Biosystems). Results were expressed relative to 18S rRNA (2ΔCT 
method) as endogenous control (TaqMan® Ribosomal RNA con-
trol Reagents kit; Applied Biosystems). cDNA was diluted 1/500 
for 18S rRNA analysis.
histology
Fifty-micrometer sections (coronal and sagittal) from 4% PFA-
fixed, frozen brains of PBS-perfused B6 mice were cut on a 
cryostat and stored in de Olmos cryoprotectant solution (24) at 
−14°C. Sections were washed in PBS and incubated for 30 min 
with 10% methanol and 10% H2O2 in PBS to block endogenous 
peroxidase. Alternatively 12 μm spinal cord sections were fixed 
with 4% PFA. After repeated rinses with 0.2% Triton X100 in PBS 
(PBST), sections were incubated for 1 h in 3% BSA in PBS to block 
unspecific binding. Next, sections were incubated overnight at 
4°C with corresponding primary antibodies: rabbit anti-Iba1 
(Wako, Neuss, Germany), hamster anti-CD11c (25) (kindly 
provided by Dr. Diego Gomez-Nicola; Centre for Biological 
Sciences, University of Southampton, SO16 6YD, Southampton, 
UK), rat anti-mouse Mac-1/CD11b (clone MCA711, AbD 
Serotec, Kidlington, UK), and rabbit anti-T-bet (H-210, Santa 
Cruz Biotechnology). Following primary antibody incubation, 
the sections were washed with PBST and incubated for 1 h with 
the appropriate secondary antibody: goat anti-Armenian hamster 
IgG-HRP (Santa Cruz Biotechnology, Heidelberg, Germany), 
goat anti-rabbit Alexa 488 (Invitrogen, Taastrup, Denmark), 
goat anti-rat Alexa 488 or biotinylated goat anti-rabbit (Abcam, 
Cambridge, UK) and PE-streptavidin (Biolegend). To visualize 
CD11c following secondary antibody incubation, the sections 
were washed with PBS and incubated for 4  min with TSA™ 
Plus Cy3 System (PerkinElmer, Skovlunde, Denmark). After 
immunofluorescent labeling, the sections were counterstained 
with DAPI and mounted with Fluorescence Mounting Medium 
(DAKO, Glostrup, Denmark). The sections were visualized on 
an Olympus FV1000MPE Confocal microscope and analyzed by 
FV10-ASW 4.06 software (Olympus, Denmark).
statistical analysis
All experiments were repeated at least three times and data are 
presented as means ± SEM. Statistical significance was assessed 
using the two-tailed Mann–Whitney U-test (GraphPad Prism 4). 
P-values <0.05 were considered significant.
results and Discussion
cD11c+ Microglia emerge During 
neuroinflammation
CD11b and CD11c form integrin heterodimers with CD18 and 
function as complement receptors. Both can be expressed by 
microglia [reviewed in Ref. (10)]. However, CD11c expression 
is usually attributed to activation of these cells. In humans, 
CD11c was shown to be constitutively expressed at a low level 
in microglia and upregulated in Alzheimer’s disease (AD) (26). 
CD11c+ Iba1+ cells were found in developing mouse brain as 
early as E16, they were also evident during postnatal neurode-
velopment P2 (27), while in adult brain they were hardly visible 
(20, 27). We have confirmed prominence of CD11c-positive cells 
in the developing brain, most of them being CCR2− CX3CR1+ 
Iba1+ microglia (unpublished data). In adult mice, only very 
few CD11c+ cells are present in the steady state, averaging 2–3% 
of total microglia (Figure  2A). However, their proportions 
increase dramatically during active neuroinflammation, such 
as in EAE (19), cuprizone-induced demyelination (23), and 
in a mouse model for neuromyelitis optica (Figure  2A), and 
also in an animal model for AD (28). Due to many phenotypic 
overlaps, bone marrow-derived macrophages (BMDM)/DC 
and microglia within the inflamed CNS are difficult to distin-
guish from each other by histology. Nevertheless, we assessed 
the localization of CD11c+ cells within the inflamed spinal 
cord. We identified three different populations of myeloid 
cells within the lesion: Iba1+ CD11c+ and Iba1+CD11c− cells, 
that are likely to include microglia/BMDM, as well as CD11c+ 
Iba1− cells, most likely DC. Beside differential expression of 
these markers, they show different morphology, ranging from 
round, as well as dendritic-like CD11c+ Iba1− cells to amoeboid 
double-positive and Iba1-single positive cells. All of them 
were uniformly distributed within the lesion, with obvious 
possibility for interaction with T cells and with each other 
(Figure  2B). These data emphasize the high morphological 
and phenotypic heterogeneity of myeloid cell populations in 
neuroinflammation.
cX3cr1 Deficiency influences eae 
susceptibility
Fractalkine receptor CX3CR1 and its ligand CX3CL1 are 
expressed within the CNS by microglia and neurons, respectively 
(29). Their interaction plays an important role in neurodevelop-
ment and has also been implicated in neuroinflammation. 
Disruption of CX3CR1–CX3CL1 axis leads to microglial 
activation and hypersensitivity and may result in neurotoxicity 
[(18) and reviewed in Ref. (30)]. For instance, mice deficient 
in CX3CR1 have been reported to develop more severe EAE 
symptoms than WT animals (31). Here, we show that mice lack-
ing CX3CR1 are more susceptible to EAE, with a significantly 
earlier onset and higher incidence of the disease (Figure 3). This 
data support conclusions from BM chimeras (31) that CX3CR1 
regulates myeloid cell and possibly microglial responses, which 
in this case would act to dampen neuroinflammation, as also 
evidenced in CX3CR1-deficient mice (18).
M1/M2 gene expression is not altered in 
cX3cr1-Deficient Microglia
Microglial phenotypic heterogeneity may also reflect func-
tional status (1, 32), as has been described for macrophages 
[reviewed in Ref. (33)]. Classically activated macrophages 
secrete inflammatory cytokines and mediators involved in host 
FigUre 3 | cX3cr1-deficient mice are more susceptible to eae. 
CX3CR1gfp/gfp and B6 mice were immunized with (MOG)p35–55 and 
monitored daily for development of EAE. The data shows significantly earlier 
onset, higher incidence of EAE in CX3CR1-deficient mice than in B6 mice. 
Data are presented as means ± SEM of at least four individual experiments 
(n ≥ 4), *P < 0.05.
FigUre 2 | cD11c+ microglia emerge in response to neuroinflammation. (a) Flow cytometry analysis shows a significant increase of CD11c+ microglia, 
presented as a percentage of total microglia, in EAE, NMO-like disease, and cuprizone-induced demyelination. Data are presented as means ± SEM of three 
individual experiments (n ≥ 6), **P < 0.01 ***P < 0.005, ****P < 0.001. (B) Representative confocal microscopic analysis of spinal cord from mice with severe EAE 
from three individual experiments. Arrowheads point to CD11c (red) single positive cells, asterisks point to Iba1 (green) single positive cells, and arrows point to cells 
co-expressing CD11c marker with Iba1.
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defense, such as tumor necrosis factor (TNFα), IL-12, or nitric 
oxide (NO) produced by inducible NO synthase (iNOS). By 
contrast, alternatively activated macrophages that are involved 
in the regulation of the immune response to limit inflamma-
tion and promote tissue repair express arginase-1 (ARG1) or 
chitinase-like proteins, such as YM1. Such cells also secrete 
growth factors, such as insulin-like growth factor 1 (IGF-1) 
or anti-inflammatory cytokine IL-10 (33). We have addressed 
functional correlates to CD11c phenotypic distinction for 
microglia sorted from the CNS of B6 and CX3CR1GFP/GFP mice 
with EAE, by analysis of mRNA levels of ARG1, YM1, iNOS, 
IL-10, and IGF1. All of them showed clear-cut preferential 
expression by one or another microglial subset (Figure  4). 
There was no difference in TNFα expression between these 
microglial populations (not shown). These results, therefore, 
point to functional distinctions between CD11c+ and CD11c− 
microglia. Moreover, CX3CR1 deficiency did not influence 
M1/M2-associated gene expression in microglia except for 
YM1, which was upregulated in CX3CR1-deficient microglia 
(Figure  4). These data suggest that the susceptibility to EAE 
in CX3CR1-deficient mice is not dependent on microglial M1/
M2 phenotype.
Myeloid cell heterogeneity in inflamed cns  
in eae
We were further interested in differences between microglia 
and blood-derived myeloid cells; thus, we compared mRNA 
levels of ARG1, YM1, iNOS, IL-10, and IGF1 between microglia 
populations and CD45highCD11c+ cells (BMDM/DC). Here, 
we show that BMDM/DC express significantly higher levels of 
ARG1, iNOS, and IL-10 than both populations of microglia, 
they also expressed significantly more transcripts of YM1 than 
CD11c+ microglia, but less than CD11c− microglia (Figure 5). 
Interestingly, while CD11c+ microglia showed high expression 
of IGF1 transcripts, neither CD11c− microglia nor infiltrating 
CD45high cells expressed significant levels of this growth fac-
tor (Figure  5). Association of IGF1 expression with CD11c+ 
microglia has also been reported in glatiramer acetate-treated 
transgenic mice with an AD-like phenotype and has been sug-
gested as a mechanistic basis for the ability of CD11c+ microglia 
to promote neurogenesis (34).
Since neurogenesis may be considered as a part of the 
anti-inflammatory or protective spectrum, we asked whether 
these cells additionally selectively expressed other regulatory 
cytokines. It was recently published that IFNβ produced by a 
FigUre 4 | Function-related gene expression by cD11c− and cD11c+ microglia in cX3cr1gfp/gfp and B6 mice in eae. Expression of IL-10, ARG1, YM1, 
iNOS, and IGF-1 in fluorescence-activated cell sorted CD11c+ microglia and CD11c− microglia from the central nervous system from mice with severe EAE were 
analyzed by quantitative real-time PCR. Data are presented as means ± SEM of three individual experiments (n ≥ 5, where n represents a pool of 2–3 individual 
mice); *P < 0.05; **P < 0.01.
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subpopulation of microglia at the peak of EAE facilitated clear-
ance of myelin debris, thus, contributing to possible explanations 
for amelioration of EAE as well as MS by IFNβ (35). Moreover, 
we have shown that experimental induction of microglial-
derived IFNβ was protective in EAE (36). We, therefore, asked 
whether CD11c+ microglia expressed IFNβ in EAE. Contrary to 
our expectations, there was no difference in expression of IFNβ 
mRNA by CD11c+ and CD11c− microglia isolated from the CNS 
of mice with EAE (Figure 6A). On this basis, there was, therefore, 
no evidence for a selective regulatory role for CD11c+ microglia. 
By contrast, infiltrating BMDM/DC expressed very low levels 
of IFNβ mRNA comparable to unmanipulated splenic CD11c+ 
cells, consistent with lack of a regulatory role for these cells, dis-
tinct from CNS-resident microglia. However, all of these brain 
myeloid populations may respond to type I IFN, as evidenced 
by equivalent expression of IRF7 and IRF3 (Figures  6B,C). 
Interestingly, IRF3 was upregulated in BMDM/DC compared 
to unmanipulated splenic CD11c+ cells (Figure 6C), suggesting 
ongoing active response within the CNS. These data further 
suggest a beneficial role for microglia in demyelinating diseases 
as well as emphasize functional distinctions between them and 
infiltrating BMDM/DC. Peripherally administered IFNβ is used 
as a first-line therapy for MS (37). IFNβ, constitutively expressed 
by microglial cells, is increased in EAE and play a protective 
role in the CNS (35, 36). Whether this protection might involve 
IFNβ-driven DC response may be speculated but would be 
consistent with the expression of the IFNβ response gene IRF7 
by DC, which we have shown.
Our findings support observations made by Yamasaki et  al. 
who used a combination of differential reporter gene expres-
sion and morphological correlates in EAE to infer that whereas 
BMDM were implicated in myelin stripping at nodes of Ranvier, 
microglia were not intimately associated with the demyelinating 
axon. Their location, relative morphology, and gene expression 
profile pointed to microglial involvement in phagocytosis and 
clearance of debris (38). Together with our findings, now based 
FigUre 5 | comparison of expression of M1/M2-associated genes in myeloid cells in cns in eae. Expression of ARG1, YM1, iNOS, IL-10, and IGF-1 in 
fluorescence-activated cell sorted CD11c+ microglia and CD11c− microglia and CD45highCD11c+ infiltrating cells (BMDM/DC) from the central nervous system from 
mice with severe EAE were analyzed by quantitative real-time PCR. Data are presented as means ± SEM of three individual experiments (n ≥ 5, where n represents 
a pool of 2–3 individual mice); *P < 0.05; **P < 0.01.
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on consensus phenotypic distinction between microglia and 
BMDM, microglia can be seen to play a beneficial role in CNS 
inflammation, as has been discussed elsewhere (39).
Myeloid cells Turn-Over During eae
Microglia have been shown to be a self-renewing population 
within the CNS. Their proliferation in response to neurodegen-
eration and their maintenance in adult mice were reported to be 
dependent on macrophage colony-stimulating factor receptor 
(CSF1R) signaling (25, 40). CSF1R signaling in response to its 
ligands, CSF1 and IL-34, induces microglial proliferation (40), 
suggesting tonic self-renewal as a component of normal homeo-
stasis. Given the emergence of CD11c+ microglia in neuroinflam-
mation, we asked whether CSF1R signaling might play a selective 
role in expansion of these cells. We used BrdU incorporation 
to assess microglial proliferation. Both CD11c+ and CD11c− 
populations of microglia proliferated equivalently during EAE 
(Figures 7A,B), arguing against proliferation per se as basis for 
relative expansion of CD11c+ cells. Consistent with this, there was 
no significant difference in expression of CSF1R by CD11c+ and 
CD11c− microglia (Figure  7C). Strikingly, infiltrating BMDM/
DC (CD45highCD11c+ cells) expressed very low levels of CSF1R 
(Figure  7C). This again emphasizes that differences between 
subsets of CNS-resident microglia are minor when both are 
compared to BMDM/DC.
BMDM/Dc but not Microglia express T-Bet 
During eae
We have shown that CD11c+ microglia in EAE express MHC-II 
and co-stimulatory molecules CD80 and CD86, and that these 
cells have potent ability to induce proliferation of antigen-primed 
CD4+ T cells (19). This has led to speculation that they may reflect 
a more DC-like subset of microglia, as was previously suggested, 
largely on the basis of morphology and CD11c expression (41). 
However, they differ from DC in their relative expression of Th1- 
and Th17-inducing cytokines and in their quantitative ability to 
induce such T cell responses, CD11c+ microglia being, notice-
ably, less effective (19). We have now further explored possible 
overlap between CD11c+ microglia and DC by comparison of 
their expression of the transcription factor T-bet. T-bet was first 
isolated as a novel Th1-specific T box transcription factor that 
controls the expression of the hallmark Th1 cytokine, IFNγ (42). 
FigUre 6 | iFnβ and iFn regulatory factors expression by microglia and infiltrating BMDM/Dc in eae. Expression of IFNβ (a), IRF7 (B), and IRF3 (c) by 
sorted myeloid cells (CD11c+ microglia, CD11c− microglia and CD45highCD11c+ BMDM/DC) from the CNS of mice with severe EAE as well as unmanipulated splenic 
CD11c+ cells was analyzed by RT-qPCR. Data are presented as means ± SEM of three individual experiments (n ≥ 5, where n represents a pool of 2–3 individual 
mice) **P < 0.01.
FigUre 7 | Proliferation of microglial and BMDM/Dc populations during eae. Representative flow cytometry profiles of six individual central nervous system 
suspensions prepared from mice with severe EAE showing BrdU incorporation by CD11c− microglia (green) and CD11c+ microglia (red) based on negative control 
(blue) (a). Flow cytometry analysis shows a significant increase in percentage of proliferating (incorporating BrdU) microglia during EAE compared to naive controls 
(B). Expression of CSF1R in fluorescence-activated cell sorted myeloid cells (CD11c+ microglia, CD11c− microglia, and CD45highCD11c+) from the central nervous 
system was analyzed by quantitative real-time PCR (c). Data are presented as means ± SEM of three individual experiments (n ≥ 5, where n represents a pool of 
2–3 individual mice) *P < 0.05.
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T-bet is also expressed by other IFNγ-producing cells including 
CD8+ T cells and NK cells, and has been shown to be expressed 
by IgG2a+ memory B cells, where it plays a role in IFNγ-mediated 
class switching as well as controlling expression of the chemokine 
receptor CXCR3 [reviewed in Ref. (43)]. T-bet is classically asso-
ciated with the Th1 CD4+ T cell subset but also controls IL23R 
FigUre 8 | T-bet is expressed by infiltrating BMDM/Dc but not by microglia in eae. (a) Expression of T-bet in sorted myeloid cells (CD11c+ microglia, 
CD11c− microglia, and CD45highCD11c+) from the central nervous system from mice with severe EAE was analyzed by quantitative real-time PCR. Data are 
presented as means ± SEM of three individual experiments (n ≥ 5, where n represents a pool of 2–3 individual mice). ND, not detected. (B) Representative confocal 
microscopic analysis of spinal cord from mice with severe EAE for four individual experiments. Arrowheads point to T-bet (red) single positive cells, asterisks point to 
Mac1/CD11b (green) single positive cells, and arrows point to cells co-expressing T-bet marker with Mac1/CD11b.
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expression by Th17 (44). It has been implicated in regulation 
of effector responses by CD8+ T cells (45, 46) and in control of 
Th-1 expression of granulocyte–macrophage colony-stimulating 
factor (GM-CSF or CSF2) (47), which has been proposed to 
be the link between pathogenic T cells and infiltrating myeloid 
cells (48). T-bet was reported to be required for Th1 and Th17 
encephalitogenicity (49), although this has been contradicted 
by later studies (50). Earlier studies had shown that T-bet was 
also expressed by DC and regulated DC functions (45, 46), and 
although reported to play a role in IFNγ production by DC, that 
is unlikely to be a major activity of this cell type. Expression of 
T-bet by DC was critical for Th1 induction and for the generation 
of T cell memory (43). T-bet was later shown to play a role in DC 
control of mast cell precursor migration (51). We compared levels 
of T-bet mRNA in microglia and BMDM/DC isolated from the 
CNS of mice with EAE. Whereas CD45highCD11c+ BMDM/DC 
robustly expressed high levels of T-bet mRNA, it was undetect-
able in most microglial samples, regardless of CD11c expression 
(Figure  8A). The expression of T-bet is, therefore, a selective 
property of infiltrating cells, likely to be specific for DC based on 
previous reports, and does not occur in CNS-resident microglia.
Glimcher and colleagues showed that DC express T-bet (45). 
Microglial expression had not previously been reported and 
our findings, somewhat surprisingly given the many overlaps in 
myeloid cell phenotype and their involvement in Th1 induction 
and chemokine responses, indicate that, in fact, these brain mac-
rophages do not express significant levels of T-bet. Thus, it was 
of interest that such a high proportion of T-bet-expressing cells 
in EAE infiltrates should turn out to be DC rather than T cells.
We were interested whether T-bet+ DC co-localized with 
microglial cells within EAE lesions. Using immunohistochemis-
try and immunofluorescence protocols, we showed that although 
some CD4+ cells co-stained with T-bet, as expected, the majority of 
T-bet+ cells did not express CD4 (data not shown), but stained for 
Mac-1/CD11b (Figure 8B). These represent the sorted CD45high 
BMDM/DC, which we showed to be the only myeloid cell source 
of T-bet mRNA (Figure 8A). EAE lesions are, therefore, highly 
heterogeneous, containing regulatory microglia with differential 
ability to present antigen to and induce cytokine responses from 
infiltrating T cells as well as infiltrating BMDM/DC that show no 
regulatory phenotype, many of which express T-bet.
All together, these data suggest that T-bet may be useful as a 
potential marker (along with myeloid markers, such as CD11b) 
for infiltrating DC in neuroinflammation, given that these popu-
lations of myeloid cells are morphologically indistinguishable.
summary
We, thus, show that CNS-resident microglia that are maintained 
at least in part by proliferation include functionally distinct 
subsets that can be distinguished by expression of CD11c. These 
subsets differ in their expression of ARG1, YM1, iNOS, IL-10, 
and IGF1. These markers have been used as a basis for a M1/M2 
phenotype classification for macrophages and were extended to 
describe microglia. Although both subpopulations of microglia 
clearly differed from each other, they did not show a pure M1 or 
M2 phenotype. This further supports the detailed transcriptional 
analysis of LPS-activated macrophages, which has revealed 
limits to such a binary distinction (52) and is in line with 
other studies where microglia have been shown to express 
M1 and M2-related genes simultaneously (53, 54). It is, thus, 
probably more useful to define phenotypic/functional cor-
relates on a case-by-case basis as, for instance, in Ref. (55). 
The issue of M1/M2 microglial phenotype and its limitations 
have been thoroughly discussed in Ref. (39).
We further show that despite these phenotypic and functional 
distinctions, microglia differ from blood-derived or BMDM/
DC in that they express the regulatory cytokine IFNβ, to which 
BMDM/DC may respond but do not express, and that BMDM/
DC express the Th1-associated transcription factor T-bet, whereas 
microglia do not. The fact that DC and microglia co-localize within 
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inflammatory lesions in EAE emphasizes that the microenviron-
ment in which autoreactive T cells are activated is complex and 
includes both regulatory and pro-pathologic myeloid cells that 
themselves may exert effector functions in the inflamed CNS.
conclusion
Over two decades of research on CD4+ T cell subsets based on 
their cytokine production profile has led to major increases in 
understanding of the inflammatory process. Myeloid cells in 
neuroinflammation also show heterogeneity and may need to be 
equivalently thoroughly studied in order to better describe their 
functions and their interaction with T cell subsets and neural cells 
in the CNS.
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